Psoriatic arthritis: epidemiology, clinical features, course, and outcome

D D Gladman, C Antoni, P Mease, D O Clegg, P Nash, D D Gladman, C Antoni, P Mease, D O Clegg, P Nash

Abstract

Psoriatic arthritis (PsA) has been defined as a unique inflammatory arthritis associated with psoriasis. Its exact prevalence is unknown, but estimates vary from 0.3% to 1% of the population. The clinical features described initially are recognised by most experienced clinicians, although they are most distinct in early disease. Initially, PsA typically presents as an oligoarticular and mild disease. However, with time PsA becomes polyarticular, and it is a severe disease in at least 20% of patients. Patients with PsA who present with polyarticular disease are at risk for disease progression. In addition to progression of clinical and radiological damage, health related quality of life is reduced among patients with PsA. It important to note that patients included in recent drug trials resemble patients followed prospectively in a clinic.

References

    1. Best Pract Res Clin Rheumatol. 2003 Jun;17(3):495-512
    1. Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii3-8
    1. Rheumatology (Oxford). 2003 Dec;42(12):1460-8
    1. J Rheumatol. 2003 Nov;30(11):2460-8
    1. Ann Rheum Dis. 2004 Feb;63(2):162-9
    1. Ann Rheum Dis. 2004 Apr;63(4):402-7
    1. Arthritis Rheum. 2004 Jun;50(6):1939-50
    1. Arthritis Rheum. 2004 Jul;50(7):2264-72
    1. Ann Rheum Dis. 1976 Jun;35(3):206-12
    1. Ann Rheum Dis. 1979 Jun;38(3):226-8
    1. Semin Arthritis Rheum. 1979 Nov;9(2):75-97
    1. Br J Rheumatol. 1984 Nov;23(4):246-50
    1. J Rheumatol. 1986 Jun;13(3):586-92
    1. Q J Med. 1987 Feb;62(238):127-41
    1. Cutis. 1990 Oct;46(4):323-9
    1. Br J Rheumatol. 1991 Aug;30(4):245-50
    1. Br J Rheumatol. 1991 Oct;30(5):339-45
    1. Br J Rheumatol. 1994 Feb;33(2):133-8
    1. Acta Derm Venereol Suppl (Stockh). 1994;186:69-70
    1. Baillieres Clin Rheumatol. 1994 May;8(2):245-61
    1. Br J Rheumatol. 1994 Sep;33(9):834-9
    1. J Rheumatol. 1995 Apr;22(4):675-9
    1. Baillieres Clin Rheumatol. 1995 May;9(2):319-29
    1. Clin Exp Rheumatol. 1995 Jul-Aug;13(4):439-43
    1. J Rheumatol. 1995 May;22(5):886-93
    1. Arthritis Rheum. 1996 Dec;39(12):2013-20
    1. J Rheumatol. 1997 Mar;24(3):511-7
    1. J Rheumatol. 1997 May;24(5):926-30
    1. Arthritis Rheum. 1997 Oct;40(10):1868-72
    1. J Rheumatol. 1998 Apr;25(4):730-3
    1. Arthritis Rheum. 1998 Jun;41(6):1103-10
    1. Am J Med Sci. 1998 Oct;316(4):234-8
    1. J Rheumatol. 1998 Nov;25(11):2146-55
    1. Ann Rheum Dis. 2005 Mar;64 Suppl 2:ii37-9; discussion ii40-1
    1. J Rheumatol. 1999 Nov;26(11):2409-13
    1. J Rheumatol. 2000 May;27(5):1247-50
    1. Lancet. 2000 Jul 29;356(9227):385-90
    1. Arthritis Rheum. 2001 Apr;45(2):151-8
    1. J Rheumatol. 2001 May;28(5):1041-4
    1. J Rheumatol. 2001 May;28(5):1045-8
    1. J Rheumatol. 2001 Aug;28(8):1842-6
    1. Acta Derm Venereol. 2002;82(2):108-13
    1. Ann Rheum Dis. 2002 Oct;61(10):911-5
    1. Ann Rheum Dis. 2003 Jan;62(1):68-70
    1. Rheumatology (Oxford). 2003 Jun;42(6):778-83
    1. Rheumatology (Oxford). 1999 Apr;38(4):332-7
    1. Am J Clin Dermatol. 2003;4(7):441-7

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa